The U.S. Food and Drug Administration announced today that they have expanded the approved use for Lucentis 0.3 mg (Genentech) to treat diabetic retinopathy in patients with diabetic macular edema. The FDA previously had approved Lucentis to treat DME and macular edema secondary to retinal vein occlusions, both of which cause fluid to leak into [Read More]
Category: Therapies, Treatments, and Procedures
FDA Approves Two Extended-Release Drug Therapies For DME
By Dan Roberts Implants devised by two different companies for treatment of diabetic macular edema (DME) have been approved by the FDA for use in the United States. The companies are Allergan and Alimera, and the new drugs are Ozurdex and Iluvien respectively. Both drugs are corticosteroids that have demonstrated effectiveness in the treatment of [Read More]
Experimental Therapies for CSR
by Dan Roberts April 2014 Updated August 18, 2018 Research has shown that corticosteroids produced by the body (endogenous) and administered externally (exogenous) can raise adrenaline levels, which can harm the central retina. Some people have high levels of endogenous steroids that can lead to a condition called central serous retinopathy (CSR), aka central serous [Read More]
U-M Kellogg Eye Center performs first two retinal prosthesis implants in U.S. since FDA approval
Kellogg retina surgeons implant Argus II Retinal Prosthesis, or ‘bionic eye,’ for two patients with end-stage retinitis pigmentosa ANN ARBOR, Mich. — Retina surgeons at the University of Michigan Kellogg Eye Center have performed the first – and second – surgeries in the United States to implant an artificial retina, or “bionic eye,” since the U.S. Food and [Read More]
Time Between Lucentis and Eylea Treatments Found To Be Similar
The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days [Read More]